182 related articles for article (PubMed ID: 36091179)
1. Potential
Li L; Liu N; Zhang H; Tao R; Zhao S; Chen Z; Fu Z; Li W; Xu L; Liu Y; Yu J; Yuan S
Front Oncol; 2022; 12():848266. PubMed ID: 36091179
[TBL] [Abstract][Full Text] [Related]
2. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment PET/CT imaging of angiogenesis based on
Li L; Ma L; Shang D; Liu Z; Yu Q; Wang S; Teng X; Zhang Q; Hu X; Zhao W; Hou W; Jin J; Kong FS; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):940-947. PubMed ID: 30187104
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
5. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
[TBL] [Abstract][Full Text] [Related]
6.
Liu J; Wu L; Liu Z; Seery S; Li J; Gao Z; Yu J; Meng X
Front Oncol; 2021; 11():671912. PubMed ID: 34150635
[TBL] [Abstract][Full Text] [Related]
7. Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
Schmainda KM; Prah MA; Marques H; Kim E; Barboriak DP; Boxerman JL
Neuro Oncol; 2021 Feb; 23(2):314-323. PubMed ID: 32678438
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
[TBL] [Abstract][Full Text] [Related]
9. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis at baseline identified by
Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
[TBL] [Abstract][Full Text] [Related]
12. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
[TBL] [Abstract][Full Text] [Related]
14. 18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
Hall DO; Hooper CE; Searle J; Darby M; White P; Harvey JE; Braybrooke JP; Maskell NA; Masani V; Lyburn ID
Nucl Med Commun; 2018 Feb; 39(2):161-170. PubMed ID: 29300270
[TBL] [Abstract][Full Text] [Related]
15. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Omuro A; Beal K; Gutin P; Karimi S; Correa DD; Kaley TJ; DeAngelis LM; Chan TA; Gavrilovic IT; Nolan C; Hormigo A; Lassman AB; Mellinghoff I; Grommes C; Reiner AS; Panageas KS; Baser RE; Tabar V; Pentsova E; Sanchez J; Barradas-Panchal R; Zhang J; Faivre G; Brennan CW; Abrey LE; Huse JT
Clin Cancer Res; 2014 Oct; 20(19):5023-31. PubMed ID: 25107913
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
[TBL] [Abstract][Full Text] [Related]
18. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
[TBL] [Abstract][Full Text] [Related]
19. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric functional MRI and
Martens RM; Koopman T; Lavini C; Ali M; Peeters CFW; Noij DP; Zwezerijnen G; Marcus JT; Vergeer MR; Leemans CR; de Bree R; de Graaf P; Boellaard R; Castelijns JA
Eur Radiol; 2021 Feb; 31(2):616-628. PubMed ID: 32851444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]